Form 8-K - Current report:
SEC Accession No. 0001171843-24-006474
Filing Date
2024-11-20
Accepted
2024-11-20 08:00:24
Documents
15
Period of Report
2024-11-20
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_112024.htm   iXBRL 8-K 15304
2 PRESS RELEASE exh_991.htm EX-99.1 8593
  Complete submission text file 0001171843-24-006474.txt   228369

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20190101.xsd EX-101.SCH 3003
4 XBRL DEFINITION FILE gnw-20190101_def.xml EX-101.DEF 25598
5 XBRL LABEL FILE gnw-20190101_lab.xml EX-101.LAB 34011
6 XBRL PRESENTATION FILE gnw-20190101_pre.xml EX-101.PRE 22139
17 EXTRACTED XBRL INSTANCE DOCUMENT f8k_112024_htm.xml XML 3441
Mailing Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6
Business Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6 310-849-8060
Aptose Biosciences Inc. (Filer) CIK: 0000882361 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32001 | Film No.: 241478313
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)